How can patients perceive and actively manage MASLD on their own?
<Hepatology Digest>: How can patients perceive and actively manage MASLD on their own to alleviate the condition and avoid further deterioration?
Current treatment status and challenges for intermediate and advanced stage HCC
<Hepatology Digest>: What is the efficacy of current treatment strategies for intermediate and advanced stage HCC, and what are the challenges and limitations associated with them?
The mechanism of tumor microenvironment affecting the occurrence and development of HCC
<Hepatology Digest>: How does the tumor immune microenvironment affect the efficacy of precision HCC therapy?
The worldwide prevalence trend of MASLD
<Hepatology Digest>: What is the prevalence trend of MASLD globally? Are there specific regions or populations that are more affected and why?
What is the association between the microbiome and autoimmune liver diseases?
<Hepatology Digest>: What role does microbiomics play in the pathogenesis of autoimmune liver diseases? What current research findings have revealed the association between the microbiome and autoimmune liver diseases?
Expert Insight | Dr. Guangxin Li: Latest Clinical Research Progress on Radiotherapy Combined with Immunotherapy for Liver Cancer
Editor's Note: In recent years, with the continuous improvement of radiotherapy technology, not only has the effectiveness of tumor reduction been optimized compared to the past, but it has also…
Dr. Guohong Han: Combining Targeted Therapy to Reduce Postoperative Liver Cancer Recurrence and Prolong Survival in Cirrhotic Patients with Anticoagulation
The 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the 2023 EASL Congress concluded successfully on June 24th in Vienna, Austria, three…
Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections
Currently, there is limited research on the natural history of disease in patients with chronic hepatitis B in the "gray zone," and there is still debate about the necessity of…
APASL 2023 | Professor Li Jun: Latest Developments in ACLF Early Warning Models, Pioneering with Large-Scale Data from China
Acute-on-Chronic Liver Failure (ACLF) is a complex syndrome characterized by acute deterioration of liver function on the background of chronic liver disease, accompanied by liver and/or extrahepatic organ failure. It poses a significant challenge in internal medicine due to its high short-term mortality rate of 50% to 90%. Early prediction of the risk of ACLF in patients and advancing the treatment window can effectively improve patient outcomes.
ILCA 2023 | Molecular typing based on fatty acid degradation metabolism helps in achieving precision treatment for liver cancer.
Primary liver cancer is currently the 4th most common malignant tumor and the 2nd leading cause of tumor-related death in China. 75%~85% of these cases are Hepatocellular carcinoma (HCC), posing a serious threat to the health and lives of Chinese citizens. In recent years, with the progress in traditional therapies like surgery, intervention, radiation, targeted therapy, and immunotherapy, there are now more options available for liver cancer patients. Recent clinical studies have shown that the combined treatment plan of atezolizumab and bevacizumab (referred to as “T+A”) can reduce the mortality risk of advanced liver cancer patients by 42% compared to the traditional targeted drug sorafenib, setting a new standard for the first-line treatment of advanced liver cancer. However, the overall survival rate of liver cancer patients remains unsatisfactory, with a 5-year survival rate of about 20%. Due to the heterogeneity of liver cancer, there is still a significant variance in the treatment response and prognosis of patients with the same clinical stage. How to select the most suitable individualized treatment method for different liver cancer patients, to maximize therapeutic effects, is a pressing issue in the clinic.